Parkinson's Drug Doesn't Increase Cardiovascular RiskAschenbrenner, Diane S. MA, RNAJN, American Journal of Nursing: February 2016 - Volume 116 - Issue 2 - p 22,23 doi: 10.1097/01.NAJ.0000480491.95233.1e Drug Watch Buy Abstract Author InformationAuthors Article MetricsMetrics The Food and Drug Administration (FDA) has determined that drugs containing entacapone, used in the management of Parkinson's disease symptoms, does not increase the risk of cardiovascular events. This announcement reverses an older FDA Drug Safety Communication in which the agency expressed concerns over possible cardiovascular events associated with use of the drug. Diane S. Aschenbrenner was previously the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.